The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Current hurdles to the translation of nanomedicines from bench to the clinic
Open accessAbstract
The field of nanomedicine has significantly influenced research areas such as drug delivery, diagnostics, theranostics, and regenerative medicine; however, the further development of this field will face significant challenges at the regulatory level if related guidance remains unclear and unconsolidated. This review describes those features and pathways crucial to the clinical translation of nanomedicine and highlights considerations for early-stage product development. These include identifying those critical quality attributes of the drug product essential for activity and safety, appropriate analytical methods (physical, chemical, biological) for characterization, important process parameters, and adequate pre-clinical models. Additional concerns include the evaluation of batch-to-batch consistency and considerations regarding scaling up that will ensure a successful reproducible manufacturing process. Furthermore, we advise close collaboration with regulatory agencies from the early stages of development to assure an aligned position to accelerate the development of future nanomedicines. Graphical abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 1×
“Targeted and non-targeted nanomedicines can improve the stability and solubility of associated active payloads, promote transport across membranes, and prolong circulation times to increase safety and efficacy [2, 3].”
BackgroundCancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Edmondson, R., Broglie, J. J., Adcock, A. F., & Yang, L. (2014) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2014.573 · Cited by 2,515
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888 · cited 1×
“In contrast, inconsistent results observed among published and industry-obtained data [227, 228] and the inability to find appropriate commercial partners due to the challenging gaps in translation have prompted the termination of the remaining studies.”
ResultTargeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Physical approaches to biomaterial design
Mitragotri, S., & Lahann, J. (2009) · Nature Materials · doi:10.1038/nmat2344 · Cited by 1,445
Nanoparticle uptake: The phagocyte problem
Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.006 · Cited by 1,411
Transparent Adult Zebrafish as a Tool for In Vivo Transplantation Analysis
White, R. M., Sessa, A., Burke, C., Bowman, T., LeBlanc, J., Ceol, C., Bourque, C., Dovey, M., Goessling, W., Burns, C. E., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.002 · Cited by 1,408
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
International Standards Organization
(2010) · Encyclopedia of Nanoscience and Society · doi:10.4135/9781412972093.n191 · Cited by 1,071
Quality by design for biopharmaceuticals
Rathore, A. S., & Winkle, H. (2009) · Nature Biotechnology · doi:10.1038/nbt0109-26 · Cited by 830
Nanomedicine: Principles, Properties, and Regulatory Issues
Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00360 · Cited by 790
Development and function of human innate immune cells in a humanized mouse model
Rongvaux, A., Willinger, T., Martinek, J., Strowig, T., Gearty, S. V., Teichmann, L. L., Saito, Y., Marches, F., Halene, S., Palucka, A. K., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2858 · Cited by 789 · cited 1×
“Relevant approaches include the development of patient-derived xenografts (PDXs), humanized mouse models [193], and genetically engineered mouse models (GEMMs) with aggressive metastasis [194]; however, the development and application of these models remain time-consuming and expensive.”
BackgroundExperimental design in chemistry: A tutorial
Leardi, R. (2009) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.06.015 · Cited by 761
Shegokar, R., & Müller, R. H. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.044 · Cited by 740
Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F., & Correia, I. J. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26845 · Cited by 721
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 588
Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020) · Biomaterials Science · doi:10.1039/d0bm00558d · Cited by 568
Quality by Design in Biopharmaceuticals
Yang, H. (2016) · doi:10.1201/9781315371726-7 · Cited by 543
Kurakula, M., & Rao, G. S. N. K. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102046 · Cited by 535
Nanomedicine scale-up technologies: feasibilities and challenges
Paliwal, R., Babu, R. J., & Palakurthi, S. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0177-9 · Cited by 466
Regulatory landscape of nanotechnology and nanoplastics from a global perspective
Allan, J., Belz, S., Hoeveler, A., Hugas, M., Okuda, H., Patri, A., Rauscher, H., Silva, P., Slikker, W., Sokull-Kluettgen, B., et al. (2021) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2021.104885 · Cited by 457
A microfluidic 3D hepatocyte chip for drug toxicity testing
Toh, Y.-C., Lim, T. C., Tai, D., Xiao, G., van Noort, D., & Yu, H. (2009) · Lab on a Chip · doi:10.1039/b900912d · Cited by 419
Regulatory aspects on nanomedicines
Sainz, V., Conniot, J., Matos, A. I., Peres, C., Zupanǒiǒ, E., Moura, L., Silva, L. C., Florindo, H. F., & Gaspar, R. S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.023 · Cited by 417
Self-citationEFSA Scientific Committee, Hardy, A., Benford, D., Halldorsson, T., Jeger, M. J., Knutsen, H. K., More, S., Naegeli, H., Noteborn, H., Ockleford, C., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5327 · Cited by 416
Challenges in nanomedicine clinical translation
Metselaar, J. M., & Lammers, T. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00740-5 · Cited by 396
Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures
Ragelle, H., Danhier, F., Préat, V., Langer, R., & Anderson, D. G. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1244187 · Cited by 390
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
The evolving landscape of drug products containing nanomaterials in the United States
D'Mello, S. R., Cruz, C. N., Chen, M.-L., Kapoor, M., Lee, S. L., & Tyner, K. M. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.67 · Cited by 345
Comparative pathogenesis of Mycobacterium marinum and Mycobacterium tuberculosis
Tobin, D. M., & Ramakrishnan, L. (2008) · Cellular Microbiology · doi:10.1111/j.1462-5822.2008.01133.x · Cited by 343
Caputo, F., Clogston, J., Calzolai, L., Rösslein, M., & Prina-Mello, A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.030 · Cited by 337
Evolution of the nanoparticle corona
Hadjidemetriou, M., & Kostarelos, K. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.61 · Cited by 336
Tumour-on-a-chip provides an optical window into nanoparticle tissue transport
Albanese, A., Lam, A. K., Sykes, E. A., Rocheleau, J. V., & Chan, W. C. W. (2013) · Nature Communications · doi:10.1038/ncomms3718 · Cited by 330
Lam, F. C., Morton, S. W., Wyckoff, J., Vu Han, T.-L., Hwang, M. K., Maffa, A., Balkanska-Sinclair, E., Yaffe, M. B., Floyd, S. R., & Hammond, P. T. (2018) · Nature Communications · doi:10.1038/s41467-018-04315-4 · Cited by 330
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.828-833.2002 · Cited by 319
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
Self-citationUnderstanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
Dobrovolskaia, M. A., & McNeil, S. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.025 · Cited by 309
Kou, L., Bhutia, Y. D., Yao, Q., He, Z., Sun, J., & Ganapathy, V. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00027 · Cited by 308
Gaspar, R., & Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.003 · Cited by 304 · cited 1×
“The strategies employed by regulatory authorities to evaluate nanomedicine safety/toxicity and compatibility are often adapted from “conventional” medicinal products [64, 149, 192, 212, 213].”
BackgroundNanotherapeutics in the EU: an overview on current state and future directions
Pepic, I., Hafner, A., Lovric, J., & Perina Lakos, G. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s55359 · Cited by 294
Could 3D models of cancer enhance drug screening?
Brancato, V., Oliveira, J. M., Correlo, V. M., Reis, R. L., & Kundu, S. C. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119744 · Cited by 281
Crist, R. M., Grossman, J. H., Patri, A. K., Stern, S. T., Dobrovolskaia, M. A., Adiseshaiah, P. P., Clogston, J. D., & McNeil, S. E. (2013) · Integrative Biology · doi:10.1039/c2ib20117h · Cited by 265
Engineered nanocrystal technology: In-vivo fate, targeting and applications in drug delivery
Pawar, V. K., Singh, Y., Meher, J. G., Gupta, S., & Chourasia, M. K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.030 · Cited by 250
On the issue of transparency and reproducibility in nanomedicine
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufés, C., Owen, A., Rannard, S., Scott, C., Chen, C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0496-9 · Cited by 242
Nanoparticle therapeutics: a personal perspective
McNeil, S. E. (2009) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.6 · Cited by 230
Dobrovolskaia, M. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.056 · Cited by 221
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Ashton, S., Song, Y. H., Nolan, J., Cadogan, E., Murray, J., Odedra, R., Foster, J., Hall, P. A., Low, S., Taylor, P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2355 · Cited by 218
Teasdale, A. (2017) · ICH Quality Guidelines · doi:10.1002/9781118971147.ch24 · Cited by 217
Influence of Nanoparticles on Blood–Brain Barrier Permeability and Brain Edema Formation in Rats
Sharma, H. S., Hussain, S., Schlager, J., Ali, S. F., & Sharma, A. (2010) · Acta Neurochirurgica Supplementum · doi:10.1007/978-3-211-98811-4_65 · Cited by 209
Mašková, E., Kubová, K., Raimi-Abraham, B. T., Vllasaliu, D., Vohlídalová, E., Turánek, J., & Mašek, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.045 · Cited by 208
Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?
Mühlebach, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.024 · Cited by 203
Read, E. K., Shah, R. B., Riley, B. S., Park, J. T., Brorson, K. A., & Rathore, A. S. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22529 · Cited by 202
Strategies to prolong the residence time of drug delivery systems on ocular surface
Grassiri, B., Zambito, Y., & Bernkop-Schnürch, A. (2021) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2020.102342 · Cited by 199
Nanoparticle clearance is governed by Th1/Th2 immunity and strain background
Jones, S. W., Roberts, R. A., Robbins, G. R., Perry, J. L., Kai, M. P., Chen, K., Bo, T., Napier, M. E., Ting, J. P. Y., DeSimone, J. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66895 · Cited by 197
Ma, H.-L., Jiang, Q., Han, S., Wu, Y., Tomshine, J. C., Wang, D., Gan, Y., Zou, G., & Liang, X.-J. (2012) · Molecular Imaging · doi:10.2310/7290.2012.00012 · Cited by 182
EDWARDS, K., & BAEUMNER, A. (2006) · Talanta · doi:10.1016/j.talanta.2005.08.031 · Cited by 178
Lessons from patient-derived xenografts for better in vitro modeling of human cancer
Choi, S. Y. C., Lin, D., Gout, P. W., Collins, C. C., Xu, Y., & Wang, Y. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.009 · Cited by 177
Nanotechnology and Nanomedicine: Going Small Means Aiming Big
Kumar Teli, M., Mutalik, S., & Rajanikant, G. K. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208992 · Cited by 177
Chu, K. S., Hasan, W., Rawal, S., Walsh, M. D., Enlow, E. M., Luft, J. C., Bridges, A. S., Kuijer, J. L., Napier, M. E., Zamboni, W. C., et al. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.11.008 · Cited by 173
New Approach for the Preparation of Nanoparticles by an Emulsification-Diffusion Method.
Leroux, J., Allémann, É., Doelker, É., & Gurny, R. (1995) · Archive ouverte UNIGE (University of Geneva) · Cited by 173
Polymeric Nanoparticles with Neglectable Protein Corona
Alberg, I., Kramer, S., Schinnerer, M., Hu, Q., Seidl, C., Leps, C., Drude, N., Möckel, D., Rijcken, C., Lammers, T., et al. (2020) · Small · doi:10.1002/smll.201907574 · Cited by 173
Gao, X., & Lowry, G. V. (2018) · NanoImpact · doi:10.1016/j.impact.2017.09.002 · Cited by 168
Mahmoudi, M. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.02.014 · Cited by 167
Zebrafish as a preclinical in vivo screening model for nanomedicines
Sieber, S., Grossen, P., Bussmann, J., Campbell, F., Kros, A., Witzigmann, D., & Huwyler, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.001 · Cited by 167
Agrahari, V., & Hiremath, P. S. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0039 · Cited by 164
In Vitro Methods for Assessing Nanoparticle Toxicity
Savage, D. T., Hilt, J. Z., & Dziubla, T. D. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8916-4_1 · Cited by 163
Regulating Nanomedicine – Can the FDA Handle It?
Bawa, R. (2011) · Current Drug Delivery · doi:10.2174/156720111795256156 · Cited by 160
Ehmann, F., Sakai-Kato, K., Duncan, R., Pérez de la Ossa, D. H., Pita, R., Vidal, J.-M., Kohli, A., Tothfalusi, L., Sanh, A., Tinton, S., et al. (2013) · Nanomedicine · doi:10.2217/nnm.13.68 · Cited by 160
The past, present, and future of breast cancer models for nanomedicine development
Boix-Montesinos, P., Soriano‐Teruel, P. M., Armiñán, A., Orzáez, M., & Vicent, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.018 · Cited by 159
Self-citationMapping of the available standards against the regulatory needs for nanomedicines
Halamoda‐Kenzaoui, B., Holzwarth, U., Roebben, G., Bogni, A., & Bremer‐Hoffmann, S. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1531 · Cited by 157
Hide and Seek: Nanomaterial Interactions With the Immune System
Fadeel, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00133 · Cited by 157
Regulating Nanomedicine at the Food and Drug Administration
Paradise, J. K. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.347 · Cited by 152
Transforming nanomedicine manufacturing toward Quality by Design and microfluidics
Colombo, S., Beck‐Broichsitter, M., Boetker, J. P., Malmsten, M., Rantanen, J., & Bohr, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.004 · Cited by 150
Nanomedicines: from bench to bedside and beyond.
Havel, H., Finch, G., Strode, P., Wolfgang, M., Zale, S., Bobe, I., Youssoufian, H., Peterson, M., & Liu, M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9961-7 · Cited by 149 · cited 1×
“Indeed, a growing body of data emerging from industry-sponsored clinical studies may ultimately enable patient selection strategies and strengthen the mechanistic underpinnings of nanomedicines [206].”
BackgroundFDA approves patisiran to treat hereditary transthyretin amyloidosis
Wood, H. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0065-0 · Cited by 145 · cited 1×
“No other oligonucleotide-based nanomedicine has been developed and authorized at the same pace, considering, for example, the amyloidosis therapeutic Onpattro® (Patisiran) [10].”
BackgroundSouto, E. B., Silva, G. F., Dias-Ferreira, J., Zielinska, A., Ventura, F., Durazzo, A., Lucarini, M., Novellino, E., & Santini, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020146 · Cited by 144
Are Existing Standard Methods Suitable for the Evaluation of Nanomedicines: Some Case Studies
Gioria, S., Caputo, F., Urbán, P., Maguire, C. M., Bremer‐Hoffmann, S., Prina‐Mello, A., Calzolai, L., & Méhn, D. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0338 · Cited by 143
Analytical methods for the control of liposomal delivery systems
Gómez‐Hens, A., & Fernández-Romero, J. M. (2005) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2005.07.006 · Cited by 141
Hubbard, G. K., Mutton, L. N., Khalili, M., McMullin, R. P., Hicks, J. L., Bianchi-Frias, D., Horn, L. A., Kulaç, İ., Moubarek, M. S., Nelson, P. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3280 · Cited by 136
The solid progress of nanomedicine
Martins, J. P., das Neves, J., de la Fuente, M., Celia, C., Florindo, H. F., Günday-Türeli, N., Popat, A., Santos, J. L., Sousa, F., Schmid, R., et al. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00743-2 · Cited by 136
Self-citationFit for consumption: zebrafish as a model for tuberculosis
Cronan, M. R., & Tobin, D. M. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.016089 · Cited by 135
Sheibani, S., Basu, K., Farnudi, A., Ashkarran, A. A., Ichikawa, M., Presley, J. F., Bui, K. H., Ejtehadi, M. R., Vali, H., & Mahmoudi, M. (2021) · Nature Communications · doi:10.1038/s41467-020-20884-9 · Cited by 135
Challenges Posed by The Scale-Up of Nanomedicines
Muthu, M. S., & Wilson, B. (2012) · Nanomedicine · doi:10.2217/nnm.12.3 · Cited by 134
Quality-by-design of nanopharmaceuticals – a state of the art
Bastogne, T. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.05.014 · Cited by 134
Cytotoxicity of Nanomaterials: Using Nanotoxicology to Address the Safety Concerns of Nanoparticles
Saifi, M. A., Khan, W., & Godugu, C. (2018) · Pharmaceutical Nanotechnology · doi:10.2174/2211738505666171023152928 · Cited by 132
Chemometrics in Process Analytical Chemistry
Miller, C. E. (2005) · Wiley eBooks · doi:10.1002/9780470988459.ch8 · Cited by 131
A review of polymers as multifunctional excipients in drug dosage form technology
Karolewicz, B. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2015.02.025 · Cited by 129
Coty, J.-B., & Vauthier, C. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.013 · Cited by 128
Gnoth, S., Jenzsch, M., Simutis, R., & Lübbert, A. (2007) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2007.03.020 · Cited by 127
Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine
Chen, X., Zhang, Y. S., Zhang, X., & Liu, C. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.09.022 · Cited by 125
Milane, L. S., & Amiji, M. M. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00911-y · Cited by 122
Nanomedicines: The magic bullets reaching their target?
Flühmann, B., Ntai, I., Borchard, G., Simoens, S., & Mühlebach, S. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.11.019 · Cited by 116
Masini, E., Planchenault, J., Pezziardi, F., Gautier, P., & Gagnol, J. P. (1985) · Inflammation Research · doi:10.1007/bf01983649 · Cited by 107
Ait‐Oudhia, S., Mager, D. E., & Straubinger, R. M. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6010137 · Cited by 105
Shaffer, S. A., Baker-Lee, C., Kennedy, J., Lai, M. S., de Vries, P. W., Buhler, K. R., & Singer, J. W. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0296-4 · Cited by 104
Hadjidemetriou, M., Al-Ahmady, Z. S., Buggio, M., Swift, J., & Kostarelos, K. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.011 · Cited by 103
Nanomedicines in the EU—Regulatory Overview
Pita, R., Ehmann, F., & Papaluca, M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9967-1 · Cited by 101
Harrington, K. J., Rowlinson‐Busza, G., Syrigos, K. N., Uster, P. S., Abra, R. M., & Stewart, J. S. W. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1232 · Cited by 96
Caputo, F., Méhn, D., Clogston, J. D., Rösslein, M., Prina‐Mello, A., Borgos, S. E., Gioria, S., & Calzolai, L. (2020) · Journal of Chromatography A · doi:10.1016/j.chroma.2020.461767 · Cited by 96
Costantino, C., Ledda, C., Squeri, R., et al. (2020) · Vaccines · doi:10.3390/vaccines8040686 · Cited by 89
Melnyk, T., Đorđević, S., Conejos‐Sánchez, I., & Vicent, M. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.007 · Cited by 86
Self-citationWei, Z., Yuan, S., Hao, J., & Fang, X. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.09.014 · Cited by 84
3D Printing in Development of Nanomedicines
Jain, K., Shukla, R., Yadav, A. K., Ujjwal, R. R., & Flora, S. J. S. (2021) · Nanomaterials · doi:10.3390/nano11020420 · Cited by 80
Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes
Méhn, D., Iavicoli, P., Cabaleiro, N., Borgos, S. E., Caputo, F., Geiss, O., Calzolai, L., Rossi, F., & Gilliland, D. D. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.03.046 · Cited by 79
Pozzi, S., Scomparin, A., Dangoor, S. I., Ajamil, D. R., Ofek, P., Neufeld, L., Krivitsky, A., Vaskovich‐Koubi, D., Kleiner, R., Dey, P., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.001 · Cited by 79
Self-citationIn vivo testing of gold nanoparticles using the Caenorhabditis elegans model organism
Gonzalez-Moragas, L., Berto, P., Vilches, C., Quidant, R., Kolovou, A., Santarella‐Mellwig, R., Schwab, Y., Stürzenbaum, S. R., Roig, A., & Laromaine, A. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.01.080 · Cited by 78
Nanotoxicology data for in silico tools: a literature review
Furxhi, I., Murphy, F., Mullins, M., Arvanitis, A., & Poland, C. A. (2020) · Nanotoxicology · doi:10.1080/17435390.2020.1729439 · Cited by 78
Delivering nanomedicines to patients: A practical guide
Eaton, M., Lévy, L., & Fontaine, O. M. A. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.02.004 · Cited by 77
Chimanuka, B., Gabriëls, M., Detaevernier, M. R., & Plaizier-vercammen, J. A. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(01)00611-2 · Cited by 77
Cationic Liposomes for Gene Delivery: Novel Cationic Lipids and Enhancement by Proteins and Peptides
Düzgüneş, N., de Ilarduya, C. T., Simões, S., Zhdanov, R. I., Konopka, K., & de Lima, M. C. P. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457403 · Cited by 75
Preclinical hazard evaluation strategy for nanomedicines
Siegrist, S., Çörek, E., Detampel, P., Sandström, J., Wick, P., & Huwyler, J. (2018) · Nanotoxicology · doi:10.1080/17435390.2018.1505000 · Cited by 74
Martins, S., Tho, I., Souto, E. B., Ferreira, D., & Brandl, M. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.12.015 · Cited by 71
Polypeptide‐Based Conjugates as Therapeutics: Opportunities and Challenges
Zagorodko, O., Arroyo‐Crespo, J. J., Nebot, V. J., & Vicent, M. J. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600316 · Cited by 70
Self-citationComparative investigations on in vitro serum stability of polymeric micelle formulations
Miller, T., Rachel, R., Besheer, A., Uezguen, S., Weigandt, M., & Goepferich, A. (2012) · Pharmaceutical Research · doi:10.1007/s11095-011-0555-x · Cited by 69
Complement activation associated with polysorbate 80 in beagle dogs
Qiu, S., Liu, Z., Hou, L., Li, Y., Wang, J., Wang, H., Du, W., Wang, W., Qin, Y., & Liu, Z. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.10.021 · Cited by 67
Protein corona fingerprinting to differentiate sepsis from non-infectious systemic inflammation
Papafilippou, L., Claxton, A., Dark, P. M., Kostarelos, K., & Hadjidemetriou, M. (2020) · Nanoscale · doi:10.1039/d0nr02788j · Cited by 67
Halamoda‐Kenzaoui, B., Ceridono, M., Colpo, P., Valsesia, A., Urbán, P., Ojea‐Jiménez, I., Gioria, S., Gilliland, D. D., Rossi, F., & Kinsner‐Ovaskainen, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141593 · Cited by 65
Challenges in the development of nanoparticle‐based imaging agents: Characterization and biology
Crist, R. M., Dasa, S. S. K., Liu, C. H., Clogston, J. D., Dobrovolskaia, M. A., & Stern, S. T. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1665 · Cited by 65
Jain, S., Batra, H., Yadav, P., & Chand, S. (2020) · Vaccines · doi:10.3390/vaccines8040649 · Cited by 59
Duro‐Castaño, A., Nebot, V. J., Niño‐Pariente, A., Armiñán, A., Arroyo‐Crespo, J. J., Paul, A., Feiner‐Gracia, N., Albertazzi, L., & Vicent, M. J. (2017) · Advanced Materials · doi:10.1002/adma.201702888 · Cited by 58
Self-citationBridging communities in the field of nanomedicine
Halamoda‐Kenzaoui, B., Baconnier, S., Bastogne, T., Bazile, D., Boisseau, P., Borchard, G., Borgos, S. E., Calzolai, L., Cederbrant, K., Felice, G. D., et al. (2019) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2019.04.011 · Cited by 57
Non-Biological Complex Drugs: The Science and the Regulatory Landscape
Crommelin, D. J. A., & de Vlieger, J. S. B. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-16241-6 · Cited by 55
Hubert, R., Roebben, G., Amenta, V., Boix, A., Luigi, C., Hendrik, E., Gaillard, C., Gibson, P. N., Thomas, L., Mech, A., et al. (2014) · Joint Research Centre (European Commission) · doi:10.2788/36343 · Cited by 51
Non-mammalian vertebrate embryos as models in nanomedicine
Giannaccini, M., Cuschieri, A., Dente, L., & Raffa, V. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.09.010 · Cited by 50
Hu, Y., Crist, R. M., & Clogston, J. D. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-02252-9 · Cited by 49
Chemometrics in Analytical Chemistry
Bhattacharjee, S. (1994) · Cited by 47
Quality by design for biopharmaceuticals: a historical review and guide for implementation
Elliott, P., Billingham, S., Bi, J., & Zhang, H. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.6 · Cited by 46
Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations
Dahlgren, D., Sjöblom, M., & Lennernäs, H. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.07.013 · Cited by 46
Stable isotope method to measure drug release from nanomedicines
Skoczen, S., McNeil, S. E., & Stern, S. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.042 · Cited by 45 · cited 2×
“The stable isotope tracer ultrafiltration assay (SITUA) represents a recently developed drug release method for assessing nanomedicine stability in human plasma[145, 162].”
BackgroundMethodTao, A., Huang, G. L., Igarashi, K., Hong, T., Liao, S., Stellacci, F., Matsumoto, Y., Yamasoba, T., Kataoka, K., & Cabral, H. (2019) · Macromolecular Bioscience · doi:10.1002/mabi.201900161 · Cited by 44
Caron, W. P., Morgan, K. P., Zamboni, B. A., & Zamboni, W. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3649 · Cited by 42
Regulatory Aspects of Oncologicals: Nanosystems Main Challenges
Gaspar, R. S., Florindo, H. F., Silva, L. C., Videira, M., Corvo, M. L., Martins, M. B. F., & Lima, B. S. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-08084-0_15 · Cited by 42
Self-citationHubert, R., Roebben, G., Boix, A., Hendrik, E., Gibson, P. N., Koeber, R., Thomas, L., Rasmussen, K., Juan, R. S., Birgit, S.-K., et al. (2015) · Joint Research Centre (European Commission) · doi:10.2788/770401 · Cited by 40
Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines
Valcourt, D. M., Kapadia, C. H., Scully, M. A., Dang, M. N., & Day, E. S. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000110 · Cited by 39
Forest, V., Hochepied, J., & Pourchez, J. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00022 · Cited by 37
Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier
Avila, Y. I., Chandler, M. R., Cedrone, E., Newton, H. S., Richardson, M., Xu, J., Clogston, J. D., Liptrott, N. J., Afonin, K. A., & Dobrovolskaia, M. A. (2021) · Molecules · doi:10.3390/molecules26030652 · Cited by 37
In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome
Junping, W., Maitani, Y., Takayama, K., & Nagai, T. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00410-5 · Cited by 36
Amenta, V., Karin, A., Boix, A., Luigi, C., Hendrik, E., Gaillard, C., Gibson, P. N., Uwe, H., Koeber, R., Thomas, L., et al. (2014) · Joint Research Centre (European Commission) · doi:10.2787/97286 · Cited by 34
What nanocrystals can offer to cosmetic and dermal formulations
Shegokar, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-42868-2.00004-8 · Cited by 33
Angiogenesis regulation by nanocarriers bearing RNA interference
Ofek, P., Tiram, G., & Satchi‐Fainaro, R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.01.008 · Cited by 31
Self-citationREGULATORY ROADMAP FOR NANOTECHNOLOGY BASED MEDICINES
Limaye, V., Fortwengel, G., & Limaye, D. (2018) · International Journal of Drug Regulatory Affairs · doi:10.22270/ijdra.v2i4.151 · Cited by 31
Liposomes: The Science and the Regulatory Landscape
Crommelin, D. J. A., Metselaar, J. M., & Storm, G. (2015) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-16241-6_3 · Cited by 24
The characterization and biodistribution of cefoxitin-loaded liposomes
Wu, P., Tsai, Y., Liao, C.-C., Chang, J., & Huang, Y. (2003) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.10.034 · Cited by 24
(EFSA), E. F. S. A., & Schoonjans, R. (2016) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2016.en-1145 · Cited by 22
Physicochemical Characterization of Polymer Nanoparticles: Challenges and Present Limitations
Clogston, J. D., Crist, R. M., & McNeil, S. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-41421-8_7 · Cited by 22
Halamoda‐Kenzaoui, B., Box, H., van Elk, M., Gaitan, S., Geertsma, R. E., Lafuente, E. G., Owen, A., del Pozo, Á., Roesslein, M., & Bremer‐Hoffmann, S. (2020) · Precision Nanomedicine · doi:10.33218/001c.13521 · Cited by 22
Importance of Physicochemical Characterization Prior to Immunological Studies
Clogston, J. D., & Patri, A. K. (2012) · Frontiers in nanobiomedical research · doi:10.1142/9789814390262_0002 · Cited by 20
Finch, G. L., Havel, H. A., Analoui, M., Barton, R. W., Diwan, A. R., Hennessy, M. G., Reddy, V. R., Sadrieh, N. K., Tamarkin, L., Wolfgang, M., et al. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9608-5 · Cited by 19
Toxicity and Regulatory Concerns for Nanoformulations in Medicine
Gaur, N., Sharma, N., Dahiya, A., Yadav, P., Ojha, H., Goyal, R. K., & Sharma, R. K. (2020) · Wiley eBooks · doi:10.1002/9781119592990.ch13 · Cited by 19
Ramanathan, R. K., Korn, R. L., Sachdev, J. C., Fetterly, G. J., Marceau, K., Marsh, V., Neil, J. M., Newbold, R. G., Raghunand, N., Prey, J. D., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ct224 · Cited by 18
Skoczen, S. L., & Stern, S. T. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7352-1_19 · Cited by 18
Recent Interventions for Nanotechnology Based Drug Products: Insights into the Regulatory Aspects
Sarwal, A., Singh, G., Singh, K. N., & Garg, S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190117094250 · Cited by 18
Rational design of an arene ruthenium chlorin conjugate for in vivo anticancer activity
Pernot, M., Barry, N. P. E., Bastogne, T., Frochot, C., Barberi‐Heyob, M., & Therrien, B. (2014) · Inorganica Chimica Acta · doi:10.1016/j.ica.2014.01.048 · Cited by 16
Nanomedicine Beyond Tumor Passive Targeting: What Next?
Longo, J. P. F., & Muehlmann, L. A. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0208 · Cited by 16
Handbook of Clinical Nanomedicine
Bawa, R., Audette, G. F., & Reese, B. (2016) · doi:10.1201/b19910 · Cited by 15
Silvestri, A., Vicente, F., Vicent, M. J., Stechmann, B., & Fecke, W. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.024 · Cited by 14
Self-citationHendriks, B. S., Shields, A. F., Siegel, B. A., Miller, K. D., Münster, P. N., Ma, C., Campbell, K., Moyo, V. M., Wickham, T. J., & LoRusso, P. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu068.1 · Cited by 11
Bavli, Y., Chen, B., Roffler, S. R., Dobrovolskaia, M. A., Elnekave, E., Ash, S., Barenholz, Y., & Turjeman, K. (2020) · Molecules · doi:10.3390/molecules25030558 · Cited by 10
Implications of Biomolecular Corona for Molecular Imaging
Mahmoudi, M., & Moore, A. V. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01559-9 · Cited by 6
Low, S. C., Hoff, D. D. V., Mita, M. M., Burris, H. A., Eisenberg, P. D., Hart, L. L., LoRusso, P. M., Weiss, G. J., Sachdev, J. C., Mita, A. C., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-911 · Cited by 2
Cited by
Clinical translation of nanomedicines: Challenges, opportunities, and keys
Younis, M. A., Tawfeek, H. M., Abdellatif, A. A. H., Abdel-Aleem, J. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114083 · Cited by 462
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
Biosafety of mesoporous silica nanoparticles; towards clinical translation
Lérida-Viso, A., Estepa-Fernández, A., García-Fernández, A., Martí-Centelles, V., & Martínez-Máñez, R. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115049 · Cited by 279
Sabit, H., Pawlik, T. M., Radwan, F., Abdel-Hakeem, M., Abdel-Ghany, S., Wadan, A.-H. S., Elzawahri, M., El-Hashash, A., & Arneth, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02357-z · Cited by 239
Ultrasmall silica nanoparticles in translational biomedical research: Overview and outlook
Singh, N., Shi, S., & Goel, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114638 · Cited by 35
Metadata
- Authors
- Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J.
- Venue
- Drug Delivery and Translational Research
- Published
- 2021-07-23
- Volume
- 12
- Issue
- 3
- Pages
- 500-525
- ISSN
- 2190-393X (ISSN-L)
- 2190-3948
- OpenAlex
- W3184755963
- Cited by
- 657
- References
- 167
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.